289 related articles for article (PubMed ID: 26850649)
1. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
3. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
Jiang NY; Dang AT; Yuan Y; Chu FI; Shabsovich D; King CR; Collins SP; Aghdam N; Suy S; Mantz CA; Miszczyk L; Napieralska A; Namysl-Kaletka A; Bagshaw H; Prionas N; Buyyounouski MK; Jackson WC; Spratt DE; Nickols NG; Steinberg ML; Kupelian PA; Kishan AU
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):628-636. PubMed ID: 31276777
[TBL] [Abstract][Full Text] [Related]
4. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
[TBL] [Abstract][Full Text] [Related]
5. Early Prostate-Specific Antigen Kinetics for Low- and Intermediate-Risk Prostate Cancer Treated With Definitive Radiation Therapy.
Pirlamarla AK; Hansen CC; Deng M; Handorf E; Paly J; Wong JK; Hallman MA; Chen DYT; Geynisman DM; Kutikov A; Horwitz EM
Pract Radiat Oncol; 2022; 12(1):60-67. PubMed ID: 34303033
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
8. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT.
Deutsch I; Zelefsky MJ; Zhang Z; Mo Q; Zaider M; Cohen G; Cahlon O; Yamada Y
Brachytherapy; 2010; 9(4):313-8. PubMed ID: 20685176
[TBL] [Abstract][Full Text] [Related]
10. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
[TBL] [Abstract][Full Text] [Related]
11. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond.
Ma TM; Roy S; Wu X; Mantz C; Fuller D; Miszczyk L; Napieralska A; Namysł-Kaletka A; Bagshaw HP; Buyyounouski MK; Glicksman R; Loblaw DA; Katz A; Upadhyaya SK; Nickols N; Steinberg ML; Philipson R; Aghdam N; Suy S; Pepin A; Collins SP; Boutros P; Rettig MB; Calais J; Wang M; Zaorsky N; Kishan AU
Radiother Oncol; 2022 Jan; 166():1-7. PubMed ID: 34774650
[TBL] [Abstract][Full Text] [Related]
12. An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer.
Marina O; Warner J; Ye H; Grills IS; Shah C; Wallace M; Gustafson GS; Brabbins DS; Martinez AA; Krauss DJ
Brachytherapy; 2014; 13(2):163-8. PubMed ID: 24295963
[TBL] [Abstract][Full Text] [Related]
13. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
[TBL] [Abstract][Full Text] [Related]
14. Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer.
Hauck CR; Ye H; Chen PY; Gustafson GS; Limbacher A; Krauss DJ
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):108-114. PubMed ID: 28586946
[TBL] [Abstract][Full Text] [Related]
15. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K
BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
Marina O; Gustafson GS; Kestin LL; Brabbins DS; Chen PY; Ye H; Martinez AA; Ghilezan MI; Wallace M; Krauss DJ
Brachytherapy; 2014; 13(1):59-67. PubMed ID: 23871661
[TBL] [Abstract][Full Text] [Related]
18. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer.
Alyamani N; Song J; van Katwyk S; Thavorn K; Renaud J; Haddad A; MacPherson M; Gaudet M
Curr Oncol; 2021 Jun; 28(4):2385-2398. PubMed ID: 34202403
[TBL] [Abstract][Full Text] [Related]
20. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]